These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12617151)

  • 1. Pathogen inactivation in cellular blood components: clinical trials and implications of introduction to transfusion medicine.
    AuBuchon JP
    Vox Sang; 2002 Aug; 83 Suppl 1():271-5. PubMed ID: 12617151
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathogen inactivation: mechanisms of action and in vitro efficacy of various agents.
    Dodd RY
    Vox Sang; 2002 Aug; 83 Suppl 1():267-70. PubMed ID: 12617150
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
    Seghatchian J; Hervig T; Putter JS
    Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogen inactivation of platelet concentrates and fresh frozen plasma.
    Jackson JE
    Br J Biomed Sci; 2003; 60(4):227-32. PubMed ID: 14725341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogen Reduction Technology in Transfusion: Where Do We Stand?
    Khurshid M; Moiz B
    J Coll Physicians Surg Pak; 2015 Nov; 25(11):779-80. PubMed ID: 26577959
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands.
    Salunkhe V; van der Meer PF; de Korte D; Seghatchian J; Gutiérrez L
    Transfus Apher Sci; 2015 Feb; 52(1):19-34. PubMed ID: 25620756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral inactivation of blood components: recent advances.
    Horowitz B; Ben-Hur E
    Transfus Clin Biol; 1996; 3(1):75-7. PubMed ID: 8640317
    [No Abstract]   [Full Text] [Related]  

  • 8. Inactivation of infectious pathogens in labile blood components: meeting the challenge.
    Corash L
    Transfus Clin Biol; 2001 Jun; 8(3):138-45. PubMed ID: 11499954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogen-reduction systems for blood components: the current position and future trends.
    Seghatchian J; de Sousa G
    Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogen inactivation: coming of age.
    Lozano M; Cid J
    Curr Opin Hematol; 2013 Nov; 20(6):540-5. PubMed ID: 24104416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacterial contamination of blood components.
    Smith LA; Wright-Kanuth MS
    Clin Lab Sci; 2003; 16(4):230-8. PubMed ID: 14626441
    [No Abstract]   [Full Text] [Related]  

  • 12. Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies.
    Webert KE; Cserti CM; Hannon J; Lin Y; Pavenski K; Pendergrast JM; Blajchman MA
    Transfus Med Rev; 2008 Jan; 22(1):1-34. PubMed ID: 18063190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
    Allain JP; Bianco C; Blajchman MA; Brecher ME; Busch M; Leiby D; Lin L; Stramer S
    Transfus Med Rev; 2005 Apr; 19(2):110-26. PubMed ID: 15852240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
    Blajchman MA
    Transfus Clin Biol; 2009 May; 16(2):70-4. PubMed ID: 19427252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.
    Osselaer JC; Doyen C; Defoin L; Debry C; Goffaux M; Messe N; Van Hooydonk M; Bosly A; Lin JS; Lin L; Corash L
    Transfusion; 2009 Jul; 49(7):1412-22. PubMed ID: 19389022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual risk of transfusion-transmitted diseases in Japan and pathogen inactivation.
    Satake M
    Vox Sang; 2002 Aug; 83 Suppl 1():277-9. PubMed ID: 12617152
    [No Abstract]   [Full Text] [Related]  

  • 17. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
    Corash L
    Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacterial contamination and proliferation during the storage of cellular blood products.
    Blajchman MA
    Vox Sang; 1998; 74 Suppl 2():155-9. PubMed ID: 9704439
    [No Abstract]   [Full Text] [Related]  

  • 19. Pathogen inactivation: emerging indications.
    Kleinman S
    Curr Opin Hematol; 2015 Nov; 22(6):547-53. PubMed ID: 26390164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates.
    Corash L
    Vox Sang; 2000; 78 Suppl 2():205-10. PubMed ID: 10938954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.